Dynamic FDG-PET/CT as an indicator of tumor aggressiveness and patient outcome in pancreatic cancer.
Ron Epelbaum(University of Bern), Alex Frenkel(Girls Incorporated), Ora Israel(Technion – Israel Institute of Technology), Natalia Sikorski(Haifa Medical Center), R. Haddad
Cited by 1
Related Papers
Curcumin as an Anti-Cancer Agent: Review of the Gap Between Basic and Clinical Applications
|Current Medicinal Chemistry|2009|480
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
|British Journal of Cancer|2014|444
<sup>18</sup>F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients
|Journal of Nuclear Medicine|2009|381
Curcumin and Gemcitabine in Patients With Advanced Pancreatic Cancer
|Nutrition and Cancer|2010|279